Abbott Laboratories (ABT) vs Merck (MRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Merck (MRK) has outperformed Abbott Laboratories (ABT) over the past year, gaining 36.8% versus a loss of 19.6%. Over five years, MRK leads with a +68.9% price change compared with -18.2% for ABT. Merck is the larger company by market cap ($329.65 billion vs $178.39 billion), about 1.8 times the size, while Abbott Laboratories is growing revenue faster (+5.7% vs +1.3%).
On valuation, Merck trades at a lower forward P/E (14.9x vs 17.3x for Abbott Laboratories). Merck offers the higher dividend yield (2.51% vs 2.45%). Merck converts more of its revenue into profit, with a net margin of 28.1% versus 14.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | MRK |
|---|---|---|
| Share price | $103.00 | $133.72 |
| Market cap | $178.39B | $329.65B |
| 1-day change | -0.84% | +0.69% |
| YTD return | -17.79% | +27.04% |
| 1-year return | -19.60% | +36.78% |
| 5-year return | -18.18% | +68.92% |
| P/E ratio (TTM) | 38.43 | 135.07 |
| Forward P/E | 17.35 | 14.92 |
| EPS (TTM) | $2.68 | $0.99 |
| Dividend yield | 2.45% | 2.51% |
| Annual dividend | $2.52 | $3.36 |
| Revenue (latest FY) | $44.33B | $65.01B |
| Revenue growth (YoY) | +5.67% | +1.31% |
| Net income (latest FY) | $6.52B | $18.25B |
| Gross margin | 56.42% | 74.80% |
| Operating margin | 18.17% | — |
| Net margin | 14.72% | 28.08% |
| 52-week high | $129.85 | $156.92 |
| 52-week low | $81.97 | $96.06 |
| Distance from 52-week high | -20.68% | -14.78% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.45% | +20.80% |
| Average volume | 8.89M | 9.81M |
| Shares outstanding | 1.73B | 2.47B |
| Employees | 122,000 | 73,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRK has outperformed ABT by 56.4 percentage points over the past year.
- Merck trades at a higher earnings multiple (135.1x vs 38.4x trailing P/E).
- Merck is more profitable, keeping 28.1 cents of every revenue dollar as net income versus 14.7 cents for Abbott Laboratories.
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About Merck
MRK stock →Merck & Co., Inc. operates as a healthcare company worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees
ABT vs MRK FAQ
Which is bigger, Abbott Laboratories or Merck?
Merck (MRK) is larger, with a market capitalization of $329.65B compared with $178.39B for Abbott Laboratories (ABT).
Which stock has performed better over the past year, ABT or MRK?
MRK returned +36.78% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or MRK?
ABT has the lower trailing P/E at 38.4, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or Merck?
Merck has the higher yield at 2.51%, compared with 2.45% for Abbott Laboratories.
Are Abbott Laboratories and Merck in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.